Paul Corn (Q139019): Difference between revisions
From geokb
(Created a new Item: Person record added from ORCID registry based on ORCID ID found as author/contributor to USGS publication) |
(Changed an Item: added Wikidata same as link) |
||||||||||||||
(6 intermediate revisions by the same user not shown) | |||||||||||||||
Property / instance of: person / reference | |||||||||||||||
Property / ORCID iD: 0000-0002-4106-6335 / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Advancements in Prostate Cancer Research / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Advancements in Prostate Cancer Research / qualifier | |||||||||||||||
last update: 26 August 2024
| |||||||||||||||
Property / knows about: Advancements in Prostate Cancer Research / qualifier | |||||||||||||||
prevalence: 281
| |||||||||||||||
Property / knows about: Advancements in Prostate Cancer Research / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Poly(ADP-ribose) Polymerase Inhibition in Cancer Therapy / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Poly(ADP-ribose) Polymerase Inhibition in Cancer Therapy / qualifier | |||||||||||||||
last update: 26 August 2024
| |||||||||||||||
Property / knows about: Poly(ADP-ribose) Polymerase Inhibition in Cancer Therapy / qualifier | |||||||||||||||
prevalence: 106
| |||||||||||||||
Property / knows about: Poly(ADP-ribose) Polymerase Inhibition in Cancer Therapy / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Lipid Metabolism in Cancer Pathogenesis / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Lipid Metabolism in Cancer Pathogenesis / qualifier | |||||||||||||||
last update: 26 August 2024
| |||||||||||||||
Property / knows about: Lipid Metabolism in Cancer Pathogenesis / qualifier | |||||||||||||||
prevalence: 77
| |||||||||||||||
Property / knows about: Lipid Metabolism in Cancer Pathogenesis / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Innate Immunity to Viral Infection / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Innate Immunity to Viral Infection / qualifier | |||||||||||||||
last update: 26 August 2024
| |||||||||||||||
Property / knows about: Innate Immunity to Viral Infection / qualifier | |||||||||||||||
prevalence: 73
| |||||||||||||||
Property / knows about: Innate Immunity to Viral Infection / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Development and Applications of Radiopharmaceuticals / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Development and Applications of Radiopharmaceuticals / qualifier | |||||||||||||||
last update: 26 August 2024
| |||||||||||||||
Property / knows about: Development and Applications of Radiopharmaceuticals / qualifier | |||||||||||||||
prevalence: 68
| |||||||||||||||
Property / knows about: Development and Applications of Radiopharmaceuticals / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Bisphosphonates in Cancer Treatment and Bone Health / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Bisphosphonates in Cancer Treatment and Bone Health / qualifier | |||||||||||||||
last update: 26 August 2024
| |||||||||||||||
Property / knows about: Bisphosphonates in Cancer Treatment and Bone Health / qualifier | |||||||||||||||
prevalence: 61
| |||||||||||||||
Property / knows about: Bisphosphonates in Cancer Treatment and Bone Health / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Genomic Landscape of Cancer and Mutational Signatures / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Genomic Landscape of Cancer and Mutational Signatures / qualifier | |||||||||||||||
last update: 26 August 2024
| |||||||||||||||
Property / knows about: Genomic Landscape of Cancer and Mutational Signatures / qualifier | |||||||||||||||
prevalence: 56
| |||||||||||||||
Property / knows about: Genomic Landscape of Cancer and Mutational Signatures / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Renal Cell Carcinoma / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Renal Cell Carcinoma / qualifier | |||||||||||||||
last update: 26 August 2024
| |||||||||||||||
Property / knows about: Renal Cell Carcinoma / qualifier | |||||||||||||||
prevalence: 53
| |||||||||||||||
Property / knows about: Renal Cell Carcinoma / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Prostate Cancer Research and Treatment / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Prostate Cancer Research and Treatment / qualifier | |||||||||||||||
last update: 26 August 2024
| |||||||||||||||
Property / knows about: Prostate Cancer Research and Treatment / qualifier | |||||||||||||||
prevalence: 34
| |||||||||||||||
Property / knows about: Prostate Cancer Research and Treatment / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Exosome Biology and Function in Intercellular Communication / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Exosome Biology and Function in Intercellular Communication / qualifier | |||||||||||||||
last update: 26 August 2024
| |||||||||||||||
Property / knows about: Exosome Biology and Function in Intercellular Communication / qualifier | |||||||||||||||
prevalence: 32
| |||||||||||||||
Property / knows about: Exosome Biology and Function in Intercellular Communication / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Ubiquitin-Proteasome Proteolytic Pathway / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Ubiquitin-Proteasome Proteolytic Pathway / qualifier | |||||||||||||||
last update: 26 August 2024
| |||||||||||||||
Property / knows about: Ubiquitin-Proteasome Proteolytic Pathway / qualifier | |||||||||||||||
prevalence: 27
| |||||||||||||||
Property / knows about: Ubiquitin-Proteasome Proteolytic Pathway / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Cancer Immunotherapy / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Cancer Immunotherapy / qualifier | |||||||||||||||
last update: 26 August 2024
| |||||||||||||||
Property / knows about: Cancer Immunotherapy / qualifier | |||||||||||||||
prevalence: 27
| |||||||||||||||
Property / knows about: Cancer Immunotherapy / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Molecular Mechanisms of Kidney Development and Disease / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Molecular Mechanisms of Kidney Development and Disease / qualifier | |||||||||||||||
last update: 26 August 2024
| |||||||||||||||
Property / knows about: Molecular Mechanisms of Kidney Development and Disease / qualifier | |||||||||||||||
prevalence: 24
| |||||||||||||||
Property / knows about: Molecular Mechanisms of Kidney Development and Disease / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: RNA Methylation and Modification in Gene Expression / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: RNA Methylation and Modification in Gene Expression / qualifier | |||||||||||||||
last update: 26 August 2024
| |||||||||||||||
Property / knows about: RNA Methylation and Modification in Gene Expression / qualifier | |||||||||||||||
prevalence: 20
| |||||||||||||||
Property / knows about: RNA Methylation and Modification in Gene Expression / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Cancer of Unknown Primary Site / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Cancer of Unknown Primary Site / qualifier | |||||||||||||||
last update: 26 August 2024
| |||||||||||||||
Property / knows about: Cancer of Unknown Primary Site / qualifier | |||||||||||||||
prevalence: 17
| |||||||||||||||
Property / knows about: Cancer of Unknown Primary Site / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Diagnosis and Treatment of Bladder Cancer / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Diagnosis and Treatment of Bladder Cancer / qualifier | |||||||||||||||
last update: 26 August 2024
| |||||||||||||||
Property / knows about: Diagnosis and Treatment of Bladder Cancer / qualifier | |||||||||||||||
prevalence: 15
| |||||||||||||||
Property / knows about: Diagnosis and Treatment of Bladder Cancer / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Epigenetic Modifications and Their Functional Implications / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Epigenetic Modifications and Their Functional Implications / qualifier | |||||||||||||||
last update: 26 August 2024
| |||||||||||||||
Property / knows about: Epigenetic Modifications and Their Functional Implications / qualifier | |||||||||||||||
prevalence: 15
| |||||||||||||||
Property / knows about: Epigenetic Modifications and Their Functional Implications / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Metabolic Reprogramming in Cancer Biology / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Metabolic Reprogramming in Cancer Biology / qualifier | |||||||||||||||
last update: 26 August 2024
| |||||||||||||||
Property / knows about: Metabolic Reprogramming in Cancer Biology / qualifier | |||||||||||||||
prevalence: 15
| |||||||||||||||
Property / knows about: Metabolic Reprogramming in Cancer Biology / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Diagnosis and Treatment of Multiple Myeloma / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Diagnosis and Treatment of Multiple Myeloma / qualifier | |||||||||||||||
last update: 26 August 2024
| |||||||||||||||
Property / knows about: Diagnosis and Treatment of Multiple Myeloma / qualifier | |||||||||||||||
prevalence: 13
| |||||||||||||||
Property / knows about: Diagnosis and Treatment of Multiple Myeloma / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Long-Term Effects of Testosterone on Health / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Long-Term Effects of Testosterone on Health / qualifier | |||||||||||||||
last update: 26 August 2024
| |||||||||||||||
Property / knows about: Long-Term Effects of Testosterone on Health / qualifier | |||||||||||||||
prevalence: 13
| |||||||||||||||
Property / knows about: Long-Term Effects of Testosterone on Health / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Mechanisms of Estrogen Receptor Signaling / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Mechanisms of Estrogen Receptor Signaling / qualifier | |||||||||||||||
last update: 26 August 2024
| |||||||||||||||
Property / knows about: Mechanisms of Estrogen Receptor Signaling / qualifier | |||||||||||||||
prevalence: 12
| |||||||||||||||
Property / knows about: Mechanisms of Estrogen Receptor Signaling / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: The p53 Signaling Network in Cancer Research / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: The p53 Signaling Network in Cancer Research / qualifier | |||||||||||||||
last update: 26 August 2024
| |||||||||||||||
Property / knows about: The p53 Signaling Network in Cancer Research / qualifier | |||||||||||||||
prevalence: 11
| |||||||||||||||
Property / knows about: The p53 Signaling Network in Cancer Research / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Fibroblast Growth Factor Signaling Pathway / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Fibroblast Growth Factor Signaling Pathway / qualifier | |||||||||||||||
last update: 26 August 2024
| |||||||||||||||
Property / knows about: Fibroblast Growth Factor Signaling Pathway / qualifier | |||||||||||||||
prevalence: 10
| |||||||||||||||
Property / knows about: Fibroblast Growth Factor Signaling Pathway / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Protein Arginine Methylation in Mammals / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Protein Arginine Methylation in Mammals / qualifier | |||||||||||||||
last update: 26 August 2024
| |||||||||||||||
Property / knows about: Protein Arginine Methylation in Mammals / qualifier | |||||||||||||||
prevalence: 10
| |||||||||||||||
Property / knows about: Protein Arginine Methylation in Mammals / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Molecular Mechanisms of DNA Damage Response / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Molecular Mechanisms of DNA Damage Response / qualifier | |||||||||||||||
last update: 26 August 2024
| |||||||||||||||
Property / knows about: Molecular Mechanisms of DNA Damage Response / qualifier | |||||||||||||||
prevalence: 10
| |||||||||||||||
Property / knows about: Molecular Mechanisms of DNA Damage Response / reference | |||||||||||||||
Property / OpenAlex ID | |||||||||||||||
Property / OpenAlex ID: A5062740919 / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / OpenAlex ID: A5062740919 / qualifier | |||||||||||||||
last update: 26 August 2024
| |||||||||||||||
Property / OpenAlex ID: A5062740919 / qualifier | |||||||||||||||
retrieved: 29 August 2024
| |||||||||||||||
Property / employer | |||||||||||||||
Property / employer: The University of Texas MD Anderson Cancer Center / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / employer: The University of Texas MD Anderson Cancer Center / qualifier | |||||||||||||||
point in time: 2024
| |||||||||||||||
Property / employer: The University of Texas MD Anderson Cancer Center / reference | |||||||||||||||
Property / same as | |||||||||||||||
Property / same as: http://www.wikidata.org/entity/Q90834109 / rank | |||||||||||||||
Normal rank |
Latest revision as of 16:11, 4 October 2024
a record for a person added from ORCID based on a contributor to a USGS publication
Language | Label | Description | Also known as |
---|---|---|---|
English | Paul Corn |
a record for a person added from ORCID based on a contributor to a USGS publication |
Statements
26 August 2024
281
1 reference
26 August 2024
106
1 reference
26 August 2024
77
1 reference
26 August 2024
73
1 reference
26 August 2024
68
1 reference
26 August 2024
61
1 reference
26 August 2024
56
1 reference
26 August 2024
53
1 reference
26 August 2024
34
1 reference
26 August 2024
32
1 reference
26 August 2024
27
1 reference
26 August 2024
27
1 reference
26 August 2024
24
1 reference
26 August 2024
20
1 reference
26 August 2024
17
1 reference
26 August 2024
15
1 reference
26 August 2024
15
1 reference
26 August 2024
15
1 reference
26 August 2024
13
1 reference
26 August 2024
13
1 reference
26 August 2024
12
1 reference
26 August 2024
11
1 reference
26 August 2024
10
1 reference
26 August 2024
10
1 reference
26 August 2024
10
1 reference